护士指导和多学科自我治疗心力衰竭的有效性:综合系统性审查
Pupalan Iyngkaran1,2, Taksh Patel3, Diana Asadi4
1Cardiology, University of Notre Dame, Sydney, NSW 2007, Australia.
Biomedicines
|August 28, 2025
概括
护士主导的慢性疾病自我管理 (CDSM) 计划对心力衰竭和减少喷射率 (HFrEF) 没有死亡率的好处,但减少了再入院和改善生活质量. 建议进行进一步研究.
科学领域:
- 心脏病学
- 公共卫生
- 护理研究
背景情况:
- 建议使用慢性疾病自我管理 (CDSM) 方案治疗心力衰竭和减少排泄率 (HFrEF).
- 关于CDSM对HFrEF的有效性的现有证据是不同的.
- 本综述侧重于护士主导的和多学科的CDSM干预在HFrEF成年人.
研究的目的:
- 综合了成年HFrEF患有充血性心力衰竭 (CHF) 的CDSM系统审查的证据.
- 批判性地评估护士主导的多学科CDSM干预措施的影响.
- 评估对死亡率,再入院,生活质量和自我管理行为的影响.
主要方法:
- 根据PRISMA 2020和AMSTAR-2指南进行系统审查.
- 搜索了多个数据库 (MEDLINE,Embase,CINAHL,Cochrane图书馆) 来查看2012年至2024年出版的评论.
- 包括对HFrEF患者的CDSM干预措施的系统审查.
主要成果:
- 分析了60项研究,其中包括22项高质量的评论.
- 对死亡益处的证据有限且不一致.
- 中等到高确定性证据表明,护士主导的CDSM改善了医院再入院率和与健康有关的生活质量 (HRQoL).
- 经常报告自我管理行为的改善 (例如,药物坚持,症状监测).
结论:
- 护士主导的CDSM干预措施持续减少HFrEF患者的再入院并改善HRQoL.
- 对于死亡益处的证据仍然没有确定性.
- 未来的研究应侧重于标准化结果,经济评估和以患者为中心,文化定制的方法.
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:28Mitral Regurgitation IV: Nursing Management
80
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
80
01:29Cardiomyopathy VI: Nursing Management
32
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
32
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505